Skip to content

SF Patholab

Active
Private limited companyfounded 20241 yr activeVerbrandhofstraat 32, 9300 Aalst, BelgiumKBO/BCE: BE 1014.514.387
Summary

SF Patholab has been active since 2024 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €117,807 and a net result of €112,807. The computed 12-month bankruptcy probability is 1.4% (low).

Checked score

Score 2025
Axes
Profitability100
Solvency97
Growth-
Track record67
Bankruptcy probability, 12 months
1.4% Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €9,000 at 30 days only on tighter terms
Liquidity ample (current ratio 3.47; short-term debt: 28.4% and cash: 98.7% of total assets), and 28.4% of the assets are financed with debt.
Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Four signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · No NACE activity registered
No NACE activity is registered in the KBO, which is more common among companies that later fail.
KBO · activities
raises risk · Young company
A young company has little track record yet and statistically fails more often than an established one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 1 year 0 10 y
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
71.6%
Return on assets
68.5%
Age of the figures
9 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-06-2026, 31 days ahead of the deadline.
NBB · 1 filing
Deviation from the deadline
2025
31 d early
← before the deadline after the deadline →
Checked, nothing found (1)
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

History

On 2 October 2024, SF Patholab was incorporated as a Private limited company.1 The company has filed annual accounts once, for fiscal year 2025.2

  1. 1Crossroads Bank for Enterprises
  2. 2National Bank, annual accounts 2025

Go further with this company

Is this your company? See how customers and banks see it.

Investigating this company? Keep it with today's facts in a case file.

Financials · fiscal year 2025, micro schema

Equity
€117,807
Total assets
€164,640
Net result
€112,807
Working capital
€115,731

Turnover and EBIT margin not published: the micro schema does not require them.

Balance-sheet composition
Assets €164,640
Fixed assets €2,077
Current assets €162,564
Equity and liabilities €164,640
Equity €117,807
Debt €46,833
Debt finances 28.4% of the balance-sheet total.
Key figures and ratios
2025 value
EBITDA
€148,976
Cash flow
€115,074
Current ratio
3.47
Debt to equity
0.40
ROE
95.8%
ROA
68.5%
Interest coverage
682.91
Debt ≤ 1 year
€46,833
Income taxes
€33,688

Peer companies

Historical observation

Of the 11,279 companies that looked in July 2024 the way this one looks now, 0.7% went bankrupt within 24 months and 97% are still going.

  • Micro
  • under 2 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
0.7% went bankrupt
2.6% stopped otherwise
97% still going

A further 0.1% stopped, but we cannot tell whether within those 24 months.

For this company itself Checked computes a higher bankruptcy probability: 1.4% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,058 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.4%
3 0.5% 0.5%
4 0.6% 0.7%
5 0.8% 0.9%
6 1.2% 1.3%
7 1.5% 1.6%
8 1.7% 1.7%
9 2.7% 2.8%
10 5.3% 5.7%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 11,279 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 · 33 lines
Balance sheet Code2025
Assets
Total assets20/58€164,640
Fixed assets21/28€2,077
Tangible fixed assets22/27€2,077
Plant, machinery and equipment23€2,077
Current assets29/58€162,564
Cash at bank and in hand54/58€162,564
Equity and liabilities
Total equity and liabilities10/49€164,640
Equity10/15€117,807
Contributions10/11€5,000
Reserves13€112,807
Distributable reserves133€112,807
Amounts payable17/49€46,833
Amounts payable within one year42/48€46,833
Trade debts44€42
Suppliers440/4€42
Taxes, remuneration and social security45€34,749
Taxes450/3€34,749
Other amounts payable47/48€12,042
Income statement Code2025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€2,267
Other operating charges640/8€655
Gross operating margin9900€149,631
Operating profit (loss)9901€146,709
Financial income75/76B€5
Recurring financial income75€5
Financial charges65/66B€218
Recurring financial charges65€218
Profit (loss) for the period before taxes9903€146,495
Income taxes67/77€33,688
Profit (loss) for the period9904€112,807
Profit (loss) for the period to be appropriated9905€112,807
Appropriation of the result
Profit (loss) to be appropriated9906€112,807
Transfer to equity691/2€112,807
To contributions691€112,807

The notes to these accounts (10 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line2025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€2,267
Other operating charges640/8€655
Gross operating margin9900€149,631
Operating profit (loss)9901€146,709
Financial income75/76B€5
Recurring financial income75€5
Financial charges65/66B€218
Recurring financial charges65€218
Profit (loss) for the period before taxes9903€146,495
Income taxes67/77€33,688
Profit (loss) for the period9904€112,807
Profit (loss) for the period to be appropriated9905€112,807
Line2025
Assets
Total assets20/58€164,640
Fixed assets21/28€2,077
Tangible fixed assets22/27€2,077
Plant, machinery and equipment23€2,077
Current assets29/58€162,564
Cash at bank and in hand54/58€162,564
Equity and liabilities
Total equity and liabilities10/49€164,640
Equity10/15€117,807
Contributions10/11€5,000
Reserves13€112,807
Distributable reserves133€112,807
Amounts payable17/49€46,833
Amounts payable within one year42/48€46,833
Trade debts44€42
Suppliers440/4€42
Taxes, remuneration and social security45€34,749
Taxes450/3€34,749
Other amounts payable47/48€12,042
Line2025
Profit (loss) for the period9904€112,807
+ Depreciation and write-downs630€2,267
Operating cash flow (approximation)€115,074

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

2026
30-06
NBB filing Annual accounts filed
fiscal year 2025 · micro schema
NBB filing
0 of 1 act read
About the unread acts

We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Aalst · 1 establishment unit since 2024
seat establishment The establishment unit on the map
Ground area
591 m²
Building footprint
156 m²
Volume, LiDAR
65 m³
Parcel 41303D0735/00X005, Flanders · tallest building 8.3 m. Linked by address, not a title deed.
2 companies at this address See who is registered here
1 establishment unit
Verbrandhofstraat 32, 9300 Aalst
Specialist medical practice
since 20242.364.880.883
1 parcel
Flanders 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
41303D0735/00X005 Flanders 591 m² 1 · 156 m² 8.3 m
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Identification & contact

Identification
Legal formPrivate limited company
Founded02-10-2024
Fiscal year end31-12
E-invoicing
Reachable via Peppol
Peppol ID 0208:1014514387
Also 9925:BE1014514387
Registered 12-02-2025

Register as of 27 September 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.